HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

BIO

Bio-Rad Laboratories, Inc. (S&P 500)

Healthcare — Medical Devices

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Hold 3.0 / 5 3 analysts
$355.57
$-22.14 (-5.86%)
Target: $328.33 (-7.7%)

Price History

52-Week Range
Sign in to add BIO to a watchlist or set price alerts.

Fundamentals

Market Cap$9.51B
P/E Ratio (TTM)43.36
Forward P/E35.86
EPS (TTM)$8.20
Dividend Yield-
Profit Margin8.59%
Revenue Growth-0.10%
ROE3.11%
Debt/Equity19.10
Recommendation Hold 3.0
Analyst Target$328.33
Analysts3
Next Earnings Aug 4, 2026 AMC
Indexes S&P 500

Technical Indicators

RSI (14)40.0
Beta1.07
SMA 20$377.42
SMA 40$373.91
52-Week High$396.23
52-Week Low$236.73
50-Day Avg$363.60
200-Day Avg$307.18
Avg Volume281.0K
Volume264.6K

Performance Analysis

BEARISH

BIO is flashing more cautionary signals — investors should monitor closely.

+ Showing strength at 75% of its 52-week range.
~ RSI at 40.0 is in neutral territory.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
- P/E of 43.4 is elevated — the market expects high growth or it may be overvalued.
- Revenue declined 0.1% year-over-year.
~ Wall Street consensus is "Hold" from 3 analysts.
- Average analyst target of $328.33 implies 7.7% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Oct 01, 2026 21:00 UTC

Back to Screener Export Report